Gang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gang Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jiangfeng Li
Zhejiang Provincial First Hospital: Zhejiang University School of Medicine First Affiliated Hospital
1 shared publication- Jiangfeng Li
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Ke Jin
Zhejiang Provincial First Hospital: Zhejiang University School of Medicine First Affiliated Hospital
1 shared publication- Ke Jin
Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
1 shared publication Liping Xie
Zhejiang Provincial First Hospital: Zhejiang University School of Medicine First Affiliated Hospital
1 shared publication- Liping Xie
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
Novel Prognosis and Therapeutic Response Model of Immune-Related lncRNA Pairs in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes, a better model therefore needs to be constructed. To provide an immune-related lncRNA (irlncRNAs) tumor prognosis model that is independent of the specific gene expression levels, we first downloaded and sorted out the data on ccRCC in the TCGA database and screened irlncRNAs using co-expression analysis and then obtained the differently expressed irlncRNA (DEirlncRNA) pairs by means of univariate analysis. In addition, we modified LASSO penalized regression. Subsequently, the ROC curve was drawn, and we compared the area under the curve, calculated the Akaike information standard value of the 5-year receiver operating characteristic curve, and determined the cut-off point to establish the best model to distinguish the high- or low-disease-risk group of ccRCC. Subsequently, we reassessed the model from the perspectives of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. A total of 17 DEirlncRNAs pairs (AL031710.1|AC104984.5, AC020907.4|AC127-24.4,AC091185.1|AC005104.1, AL513218.1|AC079015.1, AC104564.3|HOXB-AS3, AC003070.1|LINC01355, SEMA6A-AS1|CR936218.1, AL513327.1|AS005785.1, AC084876.1|AC009704.2, IGFL2-AS1|PRDM16-DT, AC011462.4|MMP25-AS1, AL662844.3I|TGB2-AS1, ARHGAP27P1|AC116914.2, AC093788.1|AC007098.1, MCF2L-AS1|AC093001.1, SMIM25|AC008870.2, and AC027796.4|LINC00893) were identified, all of which were included in the Cox regression model. Using the cut-off point, we can better distinguish patients according to different factors, such as survival status, invasive clinic-pathological features, tumor immune infiltration, whether they are sensitive to chemotherapy or not, and expression of immunosuppressive biomarkers. We constructed the irlncRNA model by means of pairing, which can better eliminate the dependence on the expression level of the target genes. In other words, the signature established by pairing irlncRNA regardless of expression levels showed promising clinical prediction value.
Open AccessNovel Prognosis and Therapeutic Response Model of Immune-Related lncRNA Pairs in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes, a better model therefore needs to be constructed. To provide an immune-related lncRNA (irlncRNAs) tumor prognosis model that is independent of the specific gene expression levels, we first downloaded and sorted out the data on ccRCC in the TCGA database and screened irlncRNAs using co-expression analysis and then obtained the differently expressed irlncRNA (DEirlncRNA) pairs by means of univariate analysis. In addition, we modified LASSO penalized regression. Subsequently, the ROC curve was drawn, and we compared the area under the curve, calculated the Akaike information standard value of the 5-year receiver operating characteristic curve, and determined the cut-off point to establish the best model to distinguish the high- or low-disease-risk group of ccRCC. Subsequently, we reassessed the model from the perspectives of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. A total of 17 DEirlncRNAs pairs (AL031710.1|AC104984.5, AC020907.4|AC127-24.4,AC091185.1|AC005104.1, AL513218.1|AC079015.1, AC104564.3|HOXB-AS3, AC003070.1|LINC01355, SEMA6A-AS1|CR936218.1, AL513327.1|AS005785.1, AC084876.1|AC009704.2, IGFL2-AS1|PRDM16-DT, AC011462.4|MMP25-AS1, AL662844.3I|TGB2-AS1, ARHGAP27P1|AC116914.2, AC093788.1|AC007098.1, MCF2L-AS1|AC093001.1, SMIM25|AC008870.2, and AC027796.4|LINC00893) were identified, all of which were included in the Cox regression model. Using the cut-off point, we can better distinguish patients according to different factors, such as survival status, invasive clinic-pathological features, tumor immune infiltration, whether they are sensitive to chemotherapy or not, and expression of immunosuppressive biomarkers. We constructed the irlncRNA model by means of pairing, which can better eliminate the dependence on the expression level of the target genes. In other words, the signature established by pairing irlncRNA regardless of expression levels showed promising clinical prediction value.
- Open Access
- 11 May 2022
- Published by Springer Nature in Research Square
Novel Prognosis and Therapeutic response model of Immune-related lncRNA pairs in Clear Cell Renal Cell Carcinoma
Background Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes. Therefore, a better model needs to be constructed. Objective To provide an immune-related lncRNA (irlncRNAs) tumor prognosis model, which independent of the specific gene expression levels. Methods First, we downloaded and sorted out the data of ccRCC in TCGA database and screened irlncRNAs by co-expression analysis, and then obtained the differently expressed irlncRNA (DEirlncRNA) pairs by univariate analysis. In addition, we modified Lasso penalized regression. Subsequently, the ROC curve was drawn, compare the area under the curve, calculate the Akaike information standard value of the 5-year receiver operating characteristic curve, and determine the cut-off point to establish the best model to distinguish the high- or low-disease-risk group of ccRCC. Subsequently, we reassessed the model from the perspectives of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. Results A total of 17 DEirlncRNAs pairs were identified, all of them were included in the Cox regression model. With the cut-off point, we can better distinguish patients according to different factors, such as survival status, invasive clinic-pathological features, tumor immune infiltration, whether chemotherapy is sensitive or not, and expression of immunosuppressive biomarkers. Conclusion We constructed irlncRNA model by pairing, which can better get rid of the dependence on the expression level of the target genes, to obtain a better clinical prediction.
- 11 May 2022
- Published by Springer Nature in Research Square
Open AccessNovel Prognosis and Therapeutic response model of Immune-related lncRNA pairs in Clear Cell Renal Cell Carcinoma
Background Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is particularly important to accurately judge the prognosis of patients. Since most tumor prediction models depend on the specific expression level of related genes. Therefore, a better model needs to be constructed. Objective To provide an immune-related lncRNA (irlncRNAs) tumor prognosis model, which independent of the specific gene expression levels. Methods First, we downloaded and sorted out the data of ccRCC in TCGA database and screened irlncRNAs by co-expression analysis, and then obtained the differently expressed irlncRNA (DEirlncRNA) pairs by univariate analysis. In addition, we modified Lasso penalized regression. Subsequently, the ROC curve was drawn, compare the area under the curve, calculate the Akaike information standard value of the 5-year receiver operating characteristic curve, and determine the cut-off point to establish the best model to distinguish the high- or low-disease-risk group of ccRCC. Subsequently, we reassessed the model from the perspectives of survival, clinic-pathological characteristics, tumor-infiltrating immune cells, chemotherapeutics efficacy, and immunosuppressed biomarkers. Results A total of 17 DEirlncRNAs pairs were identified, all of them were included in the Cox regression model. With the cut-off point, we can better distinguish patients according to different factors, such as survival status, invasive clinic-pathological features, tumor immune infiltration, whether chemotherapy is sensitive or not, and expression of immunosuppressive biomarkers. Conclusion We constructed irlncRNA model by pairing, which can better get rid of the dependence on the expression level of the target genes, to obtain a better clinical prediction.